Friday, January 09, 2026 9:48:36 AM
OTLK...64...🥳...Off my .31 Dip Alert...Have .52 Average after averaging down...
georgie18
Member Level
Re: georgie18 post# 1418
Wednesday, January 07, 2026 1:06:04 PM
Post#
1419
of 1419
OTLK...61...🥳...Big Open Gap to fill...
georgie18
Member Level
Re: georgie18 post# 710522
Wednesday, January 07, 2026 11:27:24 AM
Post#
710860
of 710873
OTLK...57...🥳...Trying to Reverse here...Off my .31 Dip Alert...
georgie18
Member Level
Re: georgie18 post# 1411
Friday, January 02, 2026 12:36:33 PM
Post#
1413
of 1417
OTLK...7179...🥳...Off the .31 Alert...On the plus side of this trade averaged down at .52 ...
georgie18
Member Level
Re: georgie18 post# 1418
Wednesday, January 07, 2026 1:06:04 PM
Post#
1419
of 1419
OTLK...61...🥳...Big Open Gap to fill...
georgie18
Member Level
Re: georgie18 post# 710522
Wednesday, January 07, 2026 11:27:24 AM
Post#
710860
of 710873
OTLK...57...🥳...Trying to Reverse here...Off my .31 Dip Alert...
georgie18
Member Level
Re: georgie18 post# 1411
Friday, January 02, 2026 12:36:33 PM
Post#
1413
of 1417
OTLK...7179...🥳...Off the .31 Alert...On the plus side of this trade averaged down at .52 ...
Recent OTLK News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/23/2026 08:30:39 PM
- Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering • GlobeNewswire Inc. • 04/23/2026 08:05:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 04/23/2026 11:30:17 AM
- Outlook Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/21/2026 08:15:44 PM
- Outlook Therapeutics Completes Federal Dispute Resolution (FDR) Meeting with FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg) • GlobeNewswire Inc. • 04/21/2026 01:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 08:15:24 PM
- Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Accepted by FDA • GlobeNewswire Inc. • 04/07/2026 12:50:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 09:04:56 PM
- Outlook Therapeutics Announces Closing of $5.0 Million Public Offering • GlobeNewswire Inc. • 03/25/2026 08:05:00 PM
- Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering • GlobeNewswire Inc. • 03/24/2026 11:00:00 AM
- Outlook Therapeutics Announces Proposed Public Offering • GlobeNewswire Inc. • 03/23/2026 09:30:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 03/23/2026 09:18:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/16/2026 01:00:28 PM
- Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note • GlobeNewswire Inc. • 03/16/2026 12:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/10/2026 08:30:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 10:01:18 PM
- Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg) • GlobeNewswire Inc. • 03/05/2026 09:15:00 PM
- Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA™ (bevacizumab gamma) in Switzerland • GlobeNewswire Inc. • 02/19/2026 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/18/2026 10:01:25 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 10:01:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 01:30:36 PM
- Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 02/17/2026 01:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/11/2026 10:00:40 PM
- Outlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response Letter • GlobeNewswire Inc. • 02/11/2026 01:45:00 PM
